BioSpace News Archive

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference 2021. Date: Thursday, July 15, 2021 Time: 10 am – 10:45 am Eastern Time

Petros Pharmaceuticals, Inc. today announced it has completed a small label comprehension pilot study, the first step in a process to obtain over the counter status.

Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech , whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases.

Lixte Biotechnology Holdings, Inc . noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer Biology program, was selected for the second time to receive the National Latino Leader Award and a scholarship to present virtually studies of LB-100 in triple negative breast cancer (TNBC) at the 2021 Society of Advancing Chicanos/Hispanics and Native Americans in the Sciences Conference.

IntuiTap Medical, a cutting-edge medical device company with technology poised to change the spinal tap, announced the closing of their Series A investment round.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced it will attend the Alzheimer’s Association International Conference in Denver , July 26-30, 2021 .

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT04951219).

The apheresis equipment market was valued at US$ 1,985.83 million in 2018 and it is projected to reach US$ 3,528.44 million in 2027; it is expected to grow at a CAGR of 6.9% from 2019 to 2027.

The global genome editing market is expected to reach US$ 10,691.0 million by 2025 from US$ 3,210.1 million in 2017; it is estimated to grow at a CAGR of 17.0% from 2018 to 2027.

The Pacemakers in healthcare market was valued at US$ 5,485.4 million in 2018 and it is projected to reach US$ 10,908.0 million by 2027; it is expected to grow at a CAGR of 8.1% from 2019 to 2027.